Coronary endothelial dysfunction is not rapidly reversible with ascorbic acid - PubMed (original) (raw)
Clinical Trial
Coronary endothelial dysfunction is not rapidly reversible with ascorbic acid
Michael E Widlansky et al. Free Radic Biol Med. 2004.
Abstract
In humans with cardiovascular risk factors, increased vascular production of superoxide anion may contribute to endothelial dysfunction by its reacting with nitric oxide and reducing its biological activity. High concentrations of ascorbic acid scavenge superoxide anion and restore normal endothelium-dependent vasodilation in humans with cardiovascular risk factors. To investigate the contribution of increased superoxide anion to endothelial dysfunction in atherosclerotic coronary arteries, we examined the effect of sequential infusions of ascorbic acid (final concentration 0.1, 1.0, and 10 mmol/L) or placebo on coronary endothelial function in 26 subjects referred for cardiac catheterization to evaluate coronary artery disease. Coronary vasomotor function was evaluated using intracoronary agonist infusion, quantitative angiography, and intracoronary Doppler measurements. At baseline, endothelium-dependent vasodilation of epicardial arteries and coronary microvessels was impaired to an equivalent extent in the ascorbic acid and placebo groups. Sequential ascorbic acid infusions had no effect on the acetylcholine-induced change in coronary artery diameter (-11+/-8, -12+/-10, and -9+/-9%) compared with the effect of placebo (-14+/-13, -16+/-10, and -13+/-9%) infusions (p=0.98). Similarly, the changes in coronary blood flow during acetylcholine infusions were equivalent during ascorbic acid (51+/-44, 67+/-66, and 62+/-52%) and placebo (61+/-104, 55+/-93, and 50+/-69%) infusions (p=0.63). Ascorbic acid also had no effect on the dilator response to intracoronary nitroglycerin (p=0.19). These data argue against an important role for superoxide-mediated "inactivation" of nitric oxide or another rapidly reversible form of oxidative stress as a mechanism of coronary endothelial dysfunction in patients with coronary atherosclerosis.
Similar articles
- Endothelial dysfunction in human disease.
Drexler H, Hornig B. Drexler H, et al. J Mol Cell Cardiol. 1999 Jan;31(1):51-60. doi: 10.1006/jmcc.1998.0843. J Mol Cell Cardiol. 1999. PMID: 10072715 Review. - Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function.
Kinlay S, Behrendt D, Fang JC, Delagrange D, Morrow J, Witztum JL, Rifai N, Selwyn AP, Creager MA, Ganz P. Kinlay S, et al. J Am Coll Cardiol. 2004 Feb 18;43(4):629-34. doi: 10.1016/j.jacc.2003.08.051. J Am Coll Cardiol. 2004. PMID: 14975474 Clinical Trial. - Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
Wassmann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G. Wassmann S, et al. Circ Res. 2003 Oct 31;93(9):e98-103. doi: 10.1161/01.RES.0000099503.13312.7B. Epub 2003 Oct 9. Circ Res. 2003. PMID: 14551237 Clinical Trial. - Role of beta2 adrenergic receptors in human atherosclerotic coronary arteries.
Barbato E, Piscione F, Bartunek J, Galasso G, Cirillo P, De Luca G, Iaccarino G, De Bruyne B, Chiariello M, Wijns W. Barbato E, et al. Circulation. 2005 Jan 25;111(3):288-94. doi: 10.1161/01.CIR.0000153270.25541.72. Epub 2005 Jan 10. Circulation. 2005. PMID: 15642763 - In vivo measurement of endothelium-dependent vasodilation with substance P in man.
Bossaller C, Reither K, Hehlert-Friedrich C, Auch-Schwelk W, Graf K, Gräfe M, Fleck E. Bossaller C, et al. Herz. 1992 Oct;17(5):284-90. Herz. 1992. PMID: 1282120 Review.
Cited by
- New development of the yolk sac theory in diabetic embryopathy: molecular mechanism and link to structural birth defects.
Dong D, Reece EA, Lin X, Wu Y, AriasVillela N, Yang P. Dong D, et al. Am J Obstet Gynecol. 2016 Feb;214(2):192-202. doi: 10.1016/j.ajog.2015.09.082. Epub 2015 Sep 30. Am J Obstet Gynecol. 2016. PMID: 26432466 Free PMC article. Review. - Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?
Halliwell B, Whiteman M. Halliwell B, et al. Br J Pharmacol. 2004 May;142(2):231-55. doi: 10.1038/sj.bjp.0705776. Br J Pharmacol. 2004. PMID: 15155533 Free PMC article. Review. - Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.
Rosenbaugh EG, Savalia KK, Manickam DS, Zimmerman MC. Rosenbaugh EG, et al. Am J Physiol Regul Integr Comp Physiol. 2013 Jun 1;304(11):R917-28. doi: 10.1152/ajpregu.00395.2012. Epub 2013 Apr 3. Am J Physiol Regul Integr Comp Physiol. 2013. PMID: 23552499 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical